Skip to main content
. 2018 Jun 1;24(6):331–345. doi: 10.1089/ten.tec.2018.0040

FIG. 8.

FIG. 8.

Immunohistochemistry after explanation of the grafts. (A) Staining for SMA demonstrating possible myofibroblast growth in animal 227 three weeks after graft implantation. In addition, sucrase-isomaltase staining is observed on the mucosal or luminal side of the graft. CD31 demonstrates the beginning of neovascularization of the graft. (B) The graft from 227 demonstrating separation of the scaffold from surrounding tissue upon harvest. The graft demonstrates staining for myofibroblast marker vimentin, goblet cell marker Muc2, and proliferation marker PCNA. (C) Graft from 226, ∼7 weeks after implantation, demonstrating positive staining for goblet cell marker Muc2, enterocyte marker SI, and for proliferation by BrdU. (D) Staining of a cell-seeded PGS graft from H173 4 weeks after implantation, demonstrating a small amount of neovascularization. (E) Cell-seeded graft from H267 demonstrating the scaffold architecture and a small amount of staining for the epithelial marker E-cadherin and proliferation marker Ki67 after implantation for 4 weeks. (F) Unseeded graft from H58 demonstrating the presence of myofibroblasts (SMA-positive cells) and the beginning of neovascularization in the presence of epithelial cells. All images are counterstained with DAPI. SI, sucrase-isomaltase; SMA, smooth muscle actin; Ecad, E-Cadherin; PCNA, proliferating cell nuclear antigen.